Wang Yuan-Yuan, Long Min-Hui, Wang Jin-Feng, Zhu He, Wang Min, Zou Min-Ji, Liu Shen, Xu Tao, Wang Jia-Xi, Xu Dong-Gang
Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):670-3.
This study was aimed to explore the influence of staphylokinase derivative (SAKD) on the hemoagglutinative and fibrinolytic systems, and to determine the safety of the staphylokinase derivative in application. The normal and model rats each 30 were divided into normal saline, SAKD and rSAK groups. The hemorrhage, bleeding time (BT), blood platelet count (BPC), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (Fg), D-dimer (D-D), plasminogen (PLG) and plasmin inhibitor activity (PI) were detected before and after the administration with staphylokinase derivative 0.5 mg/kg body weight, once three days for consecutive 15 days. The results indicated that one case of normal rats with SAKD and two cases of high fat diet model group had mild hemorrhage, all of which showed automatic hemostasis; and 3 cases in rSAK group had mild hemorrhage. And the platelet counting, D-D, PLG and PI in all groups did not significantly change. The rats of high fat diet group treated with SAKD showed the significant extension of APTT, PT and TT times, and the decrease of Fg time (p < 0.05). All the experimental results demonstrated that the influence of SAKD on the hemagglutination of the normal animals was lower, however, which can improve the high-hemagglutination status of the rats with high fat diet. It is concluded that the SAKD at the dosage of this study has the higher safety, which can alleviate the high hemagglutination symptoms of the rats with high fat diet.
本研究旨在探讨葡萄球菌激酶衍生物(SAKD)对血凝和纤溶系统的影响,并确定葡萄球菌激酶衍生物应用的安全性。将30只正常大鼠和30只模型大鼠分为生理盐水组、SAKD组和重组葡萄球菌激酶(rSAK)组。以0.5mg/kg体重的葡萄球菌激酶衍生物给药前及给药后,连续15天,每三天一次,检测出血情况、出血时间(BT)、血小板计数(BPC)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)、纤维蛋白原(Fg)、D-二聚体(D-D)、纤溶酶原(PLG)和纤溶酶抑制剂活性(PI)。结果表明,SAKD组1只正常大鼠和高脂饮食模型组2只大鼠有轻度出血,均表现为自动止血;rSAK组3只大鼠有轻度出血。所有组的血小板计数、D-D、PLG和PI均无明显变化。SAKD治疗的高脂饮食组大鼠的APTT、PT和TT时间显著延长,Fg时间缩短(p<0.05)。所有实验结果表明,SAKD对正常动物血凝的影响较小,但可改善高脂饮食大鼠的高血凝状态。结论为本研究剂量的SAKD具有较高的安全性,可缓解高脂饮食大鼠的高血凝症状。